Analysts expect Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) to post earnings of ($1.00) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Eiger Biopharmaceuticals’ earnings. The highest EPS estimate is ($0.73) and the lowest is ($1.12). Eiger Biopharmaceuticals posted earnings of ($1.34) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 25.4%. The firm is expected to announce its next quarterly earnings report on Friday, May 11th.
On average, analysts expect that Eiger Biopharmaceuticals will report full-year earnings of ($4.22) per share for the current financial year, with EPS estimates ranging from ($5.31) to ($2.32). For the next fiscal year, analysts forecast that the business will post earnings of ($3.69) per share, with EPS estimates ranging from ($5.10) to ($2.42). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Eiger Biopharmaceuticals.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.09).
Shares of EIGR stock opened at $10.85 on Monday. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.58. Eiger Biopharmaceuticals has a 12 month low of $6.10 and a 12 month high of $16.20. The stock has a market cap of $114.21, a price-to-earnings ratio of -2.23 and a beta of 1.58.
In other Eiger Biopharmaceuticals news, insider Joanne Quan sold 4,000 shares of Eiger Biopharmaceuticals stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $10.00, for a total transaction of $40,000.00. Following the completion of the sale, the insider now directly owns 4,000 shares in the company, valued at $40,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 28.80% of the stock is owned by company insiders.
Several hedge funds have recently made changes to their positions in EIGR. JPMorgan Chase & Co. grew its holdings in shares of Eiger Biopharmaceuticals by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 8,748 shares in the last quarter. OxFORD Asset Management LLP acquired a new position in shares of Eiger Biopharmaceuticals in the third quarter valued at approximately $147,000. Jennison Associates LLC acquired a new position in shares of Eiger Biopharmaceuticals in the fourth quarter valued at approximately $8,430,000. P.A.W. Capital Corp grew its holdings in shares of Eiger Biopharmaceuticals by 25.0% in the fourth quarter. P.A.W. Capital Corp now owns 100,000 shares of the biotechnology company’s stock valued at $1,395,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Unterberg Capital LLC acquired a new position in shares of Eiger Biopharmaceuticals in the fourth quarter valued at approximately $698,000. Hedge funds and other institutional investors own 68.96% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Eiger Biopharmaceuticals Inc. (EIGR) Expected to Announce Earnings of -$1.00 Per Share” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/04/16/eiger-biopharmaceuticals-inc-eigr-expected-to-announce-earnings-of-1-00-per-share.html.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.